Infusible platelet membranes

Drug Profile

Infusible platelet membranes

Alternative Names: Cyplex; IPM

Latest Information Update: 24 Dec 2008

Price : $50

At a glance

  • Originator PRP
  • Developer Cypress Bioscience
  • Class
  • Mechanism of Action Fibrinogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Haemorrhage

Most Recent Events

  • 24 Dec 2008 Discontinued - Phase-II for Haemorrhage in USA (IV)
  • 20 Aug 2002 Suspended - Phase-II for Haemorrhage in USA (IV)
  • 23 Mar 1998 Preliminary clinical results have been reported in the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top